alunbrig comprimidos recubiertos 180 mg (brigatinib)
takeda chile s.p.a. - brigatinib - sin formulas
alunbrig comprimidos recubiertos 30 mg (brigatinib)
takeda chile s.p.a. - brigatinib - sin formulas
alunbrig comprimidos recubiertos 90 mg (brigatinib)
takeda chile s.p.a. - brigatinib - sin formulas
alunbrig
takeda pharma a/s - brigatinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
alunbrig 90mg tableta recubierta
takeda s.r.l. - tableta recubierta - por tableta; brigatinib 90.000000 mg; - brigatinib
alunbrig 30mg tableta recubierta
takeda s.r.l. - tableta recubierta - por tableta; brigatinib 30.000000 mg; - brigatinib
alunbrig 180mg tableta recubierta
takeda s.r.l. - tableta recubierta - por tableta; brigatinib 180.000000 mg; - brigatinib
lorbrena 100mg tableta recubierta
pfizer s.a. - droguerÍa - tableta recubierta - por tableta - - lorlatinib